Animal Parasiticides Market

The animal parasiticides market is projected to reach USD 17.50 billion by 2031 from USD 12.98 billion in 2026, exhibiting a CAGR of 6.2% during the forecast period.

The animal parasiticides market is experiencing growth due to an increase in demand for accurate, fast, and innovative diagnostics. High prevalence of chronic, infectious, and geriatric diseases in companion animals has also boosted the market growth, particularly for preventive testing, monitoring, and treatment purposes. The rising trend for precision veterinary medicine, including molecular diagnostics, genetic analysis, and cancer-targeted analysis, and demands for non-invasive and point-of-care diagnostics have significantly influenced companion animal diagnostics practices and applications for general and specialized practices. Moreover, integration of AI, automation, and connectivity for enhanced accuracy, efficiency, and decision support for veterinary and diagnostic practitioners has also made significant contributions. Other factors, like rising demands for companion animal care and growth in investments for companion animal healthcare, have also made significant contributions to the sustained expansion of the animal parasiticides market.

To know about the assumptions considered for the study download the pdf brochure

The prominent players in the animal parasiticides market include Zoetis Services LLC (US), Merck & Co., Inc. (US), Elanco (US), Boehringer Ingelheim International GmbH (Germany), and Virbac (France), among others. These companies have implemented a variety of growth strategies, both organic and inorganic, including the introduction of new products, the formation of strategic partnerships, and penetration into emerging markets. These initiatives are aimed at enhancing their market share and diversifying their portfolios.
In July 2025, Merck & Co., Inc. (US) announced that the US FDA approved BRAVECTO QUANTUM, an extended-release injectable suspension administered once annually to provide treatment and protection for dogs against fleas and ticks.

In April 2025, Zoetis Services LLC (US) reported that the US FDA approved an expanded indication for Simparica Trio, a combination canine parasiticide that also prevents flea-transmitted tapeworm infections.

Zoetis Services LLC offers a wide range of parasiticides, vaccines, anti-infectives, diagnostics, and animal health services. It has a presence in over 100 countries and offers products for both the prevention and treatment of endoparasites. Its range of products includes Simparica and Simparica Trio, along with additional ecto- and endoparasiticides for parasite control in cattle, swine, poultry, sheep, and even aquatic species. Zoetis has undertaken several initiatives, such as expanding local manufacturing, increasing regional research and development, and forming strategic distribution partnerships. These efforts have enabled the company to address diverse parasite challenges and meet various regulatory requirements worldwide.

Merck & Co., Inc. is a global healthcare company with two main business divisions: Pharmaceuticals and Animal Health. The Animal Health division of the company provides veterinary products, which include various parasiticides and vaccines, pharmaceuticals, and health management solutions that veterinarians use on companion animals and livestock. Under Animal Health, the company operates two key segments, which are Companion Animal and Livestock, to support its parasiticide business model. The Companion Animal portfolio features leading ectoparasiticides and endoparasiticides, which include BRAVECTO and BRAVECTO PLUS, while the Livestock segment provides cattle, poultry, swine, and aquaculture farmers with parasite control products, which include both systemic and topical solutions.

Market Ranking

Zoetis Services LLC, which leads the animal parasiticides market, offers a complete range of ecto- and endoparasiticides that treat both companion animals and livestock. Merck & Co., Inc. maintains its market position through its top products, which include BRAVECTO. Elanco, which develops combination therapies and lifecycle management solutions, expands its market presence across companion and production animal markets. Boehringer Ingelheim International GmbH maintains its market strength through its extensive parasiticide portfolio, which receives support from its advanced research and development operations and its complete manufacturing capabilities. Virbac develops companion animal parasiticides, which include its exclusive, long-acting topical solutions that receive backing from its dedicated research and manufacturing operations.

Related Reports:

Animal Parasiticides Market by Type (Ectoparasiticide, Endoparasiticide, Endectocide, Spray, Feed Additives), Animal Type (Dog, Cat, Horse, Cattle, Pig, Poultry), End user (Hospital, Animal farm, Home Care Setting) & Region - Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com